Form D · Biotechnology
Mivax Therapeutics, Inc.
San Francisco, CA · CIK 0002066303
Offering snapshot reported Jan 23, 2026 · SEC filing
- Reported sold
- $108K Offering amount: $500K
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Apr 17, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 23, 2026 | Amendment | $107,500 | No comparison | 21 | SEC filing |
| Jan 23, 2026 | Amendment | $202,500 | No comparison | 21 | SEC filing |
| May 2, 2025 | Amendment | $107,500 | $0vs May 1, 2025 | 15 | SEC filing |
| May 1, 2025 | Initial | $107,500 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-544963
Some or all of non-U.S. investors were offered securities under Reg S and are excluded from Reg D reporting.
Source: Form D, filed Jan 23, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Viraj Balkrishna Deshpande | Executive |
| Pragyesh Dhungel | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
701 China Basin St Apt 605
San Francisco, CA, 94158
San Francisco, CA, 94158